Launch of 2015 SAYE Scheme

15 July 2015

Quantum Pharma Plc

("Quantum" or the "Group")

Launch of 2015 SAYE Scheme

Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce that it has today launched a Save As You Earn ('SAYE') share scheme for all employees, under which employees have been offered the opportunity to participate in the future growth of the Company via share option arrangements.

Eligible employees were invited to subscribe for options over the Company's Ordinary Shares of 10 pence each ('Ordinary Shares') with an exercise price of 129.60 pence, a 20% discount to the closing middle market price of the Company's Ordinary Shares on 19 June 2015, the trading day before the invitation to participate was made. The options have a contract start date of 1 September 2015 and are exercisable between 1 September 2018 and 28 February 2019.

A total of 188 employees elected to participate, and pursuant to these elections a total of 927,371 options over Ordinary Shares have been issued, equating to 0.742% of the current issued share capital.

Martin Such, a Director of the Company, has elected to participate in the SAYE scheme and is included in the total figures above. His individual option grant pursuant to the SAYE scheme is 13,888 shares under option.

As a result of this option grant, Martin's interest in Ordinary Shares is as follows:

*QPEBT - Quantum Pharma Employee Benefit Trust

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. The Quantum Pharma Group operates through seven business units offering a portfolio of innovative and complementary products and services to providers in primary and secondary care.

Quantum Pharmaceutical manufactures and supplies specials and special obtains for the majority of large retail pharmacy chains in the UK, as well as large pharmaceutical wholesalers, hospitals and independent pharmacies. Specials are bespoke, non-licensed medicines which can be custom manufactured as a one-off or procured for individual patient needs where a clinician deems a patient requires a bespoke formulation for their treatment. The company can manufacture and supply bespoke medicines in as little as 15 hours and regularly services around 6,500 pharmacies across the UK with a choice of more than 22,000 specials or special obtains.

Quantum Aseptic Services manufactures aseptically prepared sterile intravenous products, either individually for named patients or in batches. Serving the hospital market (both NHS and private) and homecare patients, its unique, six-day-a-week, next morning (by 10.30am) compounding service enables many hospitals to offer chemotherapy treatment five days a week, unencumbered by the delays of aseptic production.

UL Medicines sources and supplies unlicensed imported medicines and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas. The company offers approximately 500 imported medicines sourced from more than 24 countries, as well as a specialist over-labelling service that translates accompanying local language patient documentation into English.

Biodose® is the only medicines delivery system that accommodates both liquid and solid medication, supporting medicines administration and adherence for 50,000 patients with complex medication regimes, their carers and clinicians. Building on its success, Biodose Connect®, due for launch in early 2016, incorporates telemedicines technology to provide live, remote monitoring and management of patient adherence to prevent avoidable and costly hospital admissions.

Biodose Services® provides pre-prepared medication regimes to care homes and delivery of medication to the home. Biodose Services is the UK's largest provider of the Biodose system and operates from a 7,600ft purpose-designed specialist pharmacy in West Yorkshire. The company also offers a range of homecare services to the NHS, private clinics and pharmaceutical companies including the Stork Fertility Service®, premium homecare for patients receiving fertility treatment.

Colonis is a product development business which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated product status. Colonis launched its first licensed product, Aviticol in December 2014. Colonis has also launched one regulated product and a second licensed product is being manufactured ready for launch. The company is currently working on a significant pipeline of approximately 60 products (SKUs) across a growing number of therapeutic areas, 10 of which have been submitted for approval to the MHRA.

Lamda is a full service contract development specialist with customers in the UK, Ireland, Germany, France, Italy, Sweden, Greece and Cyprus. As well as providing in-house development for the Colonis pipeline, Lamda provides a fully outsourced research and development service for pharmaceutical companies looking to develop pharmaceutical forms or to license medicinal products.

For further information, please visit www.quantumpharmagroup.com.